Browse

Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy

Cited 36 time in Web of Science Cited 46 time in Scopus
Issue Date
2007
Publisher
Wiley-Blackwell
Citation
Helicobacter 2006;12:623-8
Keywords
Amoxicillin/administration & dosage/adverse effects/therapeutic useAnti-Bacterial Agents/*administration & dosage/adverse effects/therapeuticAza Compounds/*administration & dosage/adverse effects/therapeutic useDrug Administration ScheduleDrug Therapy, CombinationHelicobacter Infections/*drug therapyHelicobacter pylori/*drug effectsMetronidazole/administration & dosage/adverse effects/therapeutic useOmeprazole/administration & dosage/adverse effects/therapeutic useOrganometallic Compounds/administration & dosage/adverseeffects/therapeutic usePatient ComplianceQuinolines/*administration & dosage/adverse effects/therapeutic useTetracycline/administration & dosage/adverse effects/therapeutic use
Abstract
BACKGROUND AND AIM: The aim of this study was to test the efficacy of 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy for the second-line treatment of Helicobacter pylori infection. METHODS: One hundred and ninety-two patients who had failed previous H. pylori eradication on standard triple therapy were randomized to one of two regimens: 1, moxifloxacin (400 mg q.d.), amoxicillin (1000 mg b.i.d.), and esomeprazole (20 mg b.i.d.) for 10 days (the 10MEA group), or 2, esomeprazole (20 mg b.i.d.), tripotassium dicitrate bismuthate (300 mg q.i.d.), metronidazole (500 mg t.i.d.), and tetracycline 500 mg (q.i.d.) for 14 days (the 14EBMT group). The eradication rates, drug compliances, and side-effect rates of these two regimens were compared. RESULTS: Eradication rates by intention-to-treat and per-protocol analyses in the 10MEA and 14EMBT groups were 71.9% and 82.6%, and 71.7% and 90.5% (p = .973 and .321), respectively. The 10MEA group was significantly superior to the 14EMBT group in terms of side-effect rates (12.2% vs. 39.6%, p = .001), and discontinuation rates due to side-effects were lower in the 10MEA group than in the 14EMBT group (0.7% vs. 13.2%, p < .001). Moreover, compliance was higher in the 10MEA group (94.2% (131/139)) than in the 14EBMT group (83.0% (44/53)) (p = .014). CONCLUSION: The 10-day moxifloxacin-based triple therapy was found to have a high eradication rate with few side-effects and good drug compliance. These findings suggest that this regimen is a safe and effective second-line treatment option for H. pylori infection in Korea.
ISSN
1083-4389 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18001404

https://hdl.handle.net/10371/22174
DOI
https://doi.org/10.1111/j.1523-5378.2007.00548.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Program in Clinical Pharmacology (협동과정-임상약리학전공)Journal Papers (저널논문_협동과정-임상약리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse